Our Company and our Board actively promote and foster an inclusive culture to enable an environment where the unique characteristics, backgrounds and beliefs of our teammates can drive the groundbreaking, strategic thinking that gives our Company its competitive edge in a diverse marketplace.
Our Board does not establish specific goals with respect to diversity; rather, Board diversity is a consideration in the director succession planning and nomination process. Diversity is also a factor in the overall assessment of the Board’s composition and effectiveness. Under the Nominating, Governance & Sustainability Committee Charter, the Board has further committed to include, and require any third-party search firm that it engages to include, candidates with diversity of race, ethnicity and gender in the slate of candidates considered by the Committee and/or the Board for nomination to the Board.
The illustrations below depict independence, age, tenure and diversity represented in the composition of our director nominees.
Board Refreshment
The Committee and the Board follow a thoughtful refreshment process to ensure the Board’s composition best reflects the most appropriate mix of skills and experiences to provide robust oversight of the Company and its strategic priorities. The Committee and the Board also specifically strive to maintain a balance of tenure on the Board. Longer-serving directors bring valuable experience and a deep understanding of our complex business and industry, along with a historical perspective of our long-term successes, challenges and business cycles, and how these past experiences may inform our current strategy. Newer directors are also critical to the advancement of our strategy, bringing new skills and experiences and contributing fresh perspectives. The Board has established a policy that non-employee directors must retire at the first annual meeting following his or her seventy-third birthday. To encourage director refreshment, there are no exemptions or conditions in this policy.
In addition to Board refreshment, our Board maintains a regular practice of evaluation and refreshment of Committee composition, including leadership roles. Over the last three years, our Board refreshed the leadership and composition of our Nominating, Governance & Sustainability Committee, Organization & Compensation Committee, and Technology Committee.
| · · · |
|---|
| | |
|---|
| | Proposal One • 2026 Proxy Statement | Humana | | | 5 | |
|---|
Director Nominee Biographies
| | | | | | | | | | | | | | | |
|---|
| | Kurt J. Hilzinger | | | | Chairman of the Board, Director | | | | Age 65 | Male | White | | | | | |
|---|
| | | | | | Independence | | | | Committees | | | | |
|---|
| | Independent Director Since 2003 | | | | • Investment Committee | | | | |
|---|
| | Skills and Expertise | | | | | | | | |
|---|
| | • Public Company COO Experience • Financial Oversight, Capital Allocation and Corporate Transactions • Healthcare Industry Experience | | | | • Government Relations/Public Policy • Risk Assessment • Corporate Governance | | | | | | |
|---|
| | Executive Advisor, Former Partner Court Square Capital Partners Former Director, President andCOO AmerisourceBergen Corp. | | | | Professional Summary | | | | | | |
|---|
| | Kurt J. Hilzinger was initially elected to the Board in July 2003 and was elected Chairman of the Board effective January 1, 2014. Mr. Hilzinger served as Lead Director from August 2010 until his appointment as Chairman. Mr. Hilzinger is an Executive Advisor and former Partner at Court Square Capital Partners (Court Square), an independent private equity firm, having held this position since November 2007. At Court Square, Mr. Hilzinger focuses principally on investments in the healthcare industry. | | | | | | |
|---|
| | | | | | Prior to Court Square, Mr. Hilzinger was a Director of AmerisourceBergen Corporation from March 2004 to November 2007; having previously served as President and Chief Operating Officer of AmerisourceBergen Corporation from October 2002 to November 2007, and as Executive Vice President and Chief Operating Officer from August 2001 to October 2002. As a distinguished financial executive and operator, Mr. Hilzinger led the recapitalization and initial public offering or Amerisource Health Corp. and the successful integration or Amerisource Health Corp. and Bergen Brunswig Corp. in the creation of AmerisourceBergen Corp. (now Cencora Corp.). In addition to his integration responsibilities, Mr. Hilzinger held enterprise-wide P&L responsibility while overseeing the integration of 30+ acquisitions and the transformation of the business model to fee or services. Mr. Hilzinger has significant government affairs experience interacting with the FTC, the FDA, and the DEA, and while serving as Chairman of the Healthcare Distribution Alliance (HDA). Mr. Hilzinger is a thought leader in the healthcare sector, with a successful career track record of investments in pharmaceutical services and commercialization. | | | | | | |
|---|
| | Other Public Company Boards (1) | | | | Board Aptitude | | | | | | |
|---|
| | • Outlook Therapeutics, Inc. | | | | The Board believes that Mr. Hilzinger’s distinguished experience as a financial executive, professional healthcare investor, and operating executive contributes significantly to the Board's composition. His extensive tenure as a Partner at a leading private equity firm provides a sophisticated, shareholder-aligned perspective on capital allocation, risk oversight and disciplined investment evaluation. Mr. Hilzinger’s deep financial expertise in the healthcare sector includes a track record of overseeing and leading M&A/transaction integrations, recapitalizations, and initial public offerings and provides the Board with invaluable strategic insight. | | | | | | |
|---|
| · · · |
|---|
| | |
|---|
| | 6 | | | Humana | 2026 Proxy Statement • Proposal One | |
|---|
| | | | | | | | | | | | | | | |
|---|
| | James A. Rechtin | | | | Director | | | | Age 55 | Male | White | | | | | |
|---|
| | | | | | Independence | | | | Committees | | | | | |
|---|
| | Non-Independent Director Since 2024 | | | | • No Committee Roles | | | | |
|---|
| | Skills and Expertise | | | | | | |
|---|
| | • CEO Experience • Financial Oversight, Capital Allocation and Corporate Transactions • Healthcare Industry Experience | | | | • Marketing/Consumer Insights • Risk Assessment • Corporate Governance | | | | |
|---|
| | President & CEO Humana Inc. Former President & CEOEnvision Healthcare | | | | Professional Summary | | | | | | |
|---|
| | James (Jim) Rechtin, joined Humana in January 2024, having served as President and Chief Operating Officer until July 2024. Under his leadership, Humana operates as a leading integrated care delivery model centered on improving health outcomes, driving lower costs, enhancing quality, and providing a simple and personalized member and patient experience. | | | | | | |
|---|
| | | | | | Prior to joining Humana, Mr. Rechtin served as President and CEO at Envision Healthcare. He has more than 22 years of health care experience with a focus on the delivery of value-based care in various medical group settings, including a deep understanding of Medicare Advantage. Prior to joining Envision, Mr. Rechtin served as President of OptumCare, part of UnitedHealth Group. Before that, Mr. Rechtin was with DaVita Medical Group and played the dual roles of Senior Vice President of Corporate Strategy and President of DaVita Medical Group’s California market. Further, he is a 14-year veteran of Bain & Company, highlighting his depth of experience in health care mergers and the overall health care sector. | | | | | | |
|---|
| | Other Public Company Boards (0) | | | | Board Aptitude | | | | |
|---|
| | | | | | The Board believes that Mr. Rechtin brings to Humana a strong combination of operational, industry, M&A and CEO expertise. Mr. Rechtin’s solid leadership acumen in the healthcare sector, coupled with his deep understanding of the Company’s core business, offer practical perspectives to the Board. Further, his first-hand experience leading through the challenges and opportunities of a changing health care services continuum will help accelerate the Company’s integrated care strategy at pace. | | | | | | |
|---|
| · · · |
|---|
| | |
|---|
| | Proposal One • 2026 Proxy Statement | Humana | | | 7 | |
|---|
| | | | | | | | | | | | | | | |
|---|
| | Raquel C. Bono, M.D | | | | Director | | | | Age 69 | Female | Asian | | | | | |
|---|
| | | | | | Independence | | | | Committees | | | | | |
|---|
| | Independent Director Since 2020 | | | | • Audit Committee • Clinical Quality Committee | | | | |
|---|
| | Skills and Expertise | | | | | | |
|---|
| | • CEO Experience • Financial Oversight, Capital Allocation and Corporate Transactions • Healthcare Industry Experience | | | | • Government Relations/Public Policy • Risk Assessment • Sustainability/ESG | | | | |
|---|
| | Principal RCB Consulting CEO & Chief of Surgical Innovation Medical iSight Former CEO and Director Defense Health Agency (DHA) Former Chief Health OfficerViking Cruises | | | | Professional Summary | | | | | | |
|---|
| | Raquel C. Bono, M.D. was initially elected to the Board in September 2020. Dr. Bono is a Principal at RCB Consulting having held this position since October 2019, and serves as CEO and Chief of Surgical Innovation at Medical iSight, having held this position since 2023. Dr. Bono was formerly Chief Health Officer at Viking Cruises from November 2020 until her retirement in December 2023. | | | | | | |
|---|
| | Prior to Viking Cruises, Dr. Bono, a board-certified trauma surgeon and retired Vice Admiral, U.S. Navy Medical Corps, served as the Chief Executive Officer and Director for the Defense Health Agency (DHA). In this capacity, Dr. Bono led a joint, integrated combat support agency that enables all branches of the U.S. military medical services to provide health care services to combatant commands in times of both peace and war. Dr. Bono integrated an unprecedented $50 billion worldwide health care enterprise for the Army, Navy, Air Force, and Marine Corps, composed of 50 hospitals and 300 clinics that provide care to 9.5 million military personnel, oversaw the Department of Defense deployment of the electronic health record, and facilitated the collaboration between the largest federated health systems of the Department of Defense and Department of Veterans Affairs (VA). | | | | | | |
|---|
| | | | | | An American College of Surgeons (ACS) Fellow since 1991, Dr. Bono served on the ACS Board of Governors and the Governors Health Policy and Advocacy Workgroup. She has been honored with the Defense Distinguished Service Medal, three Defense Superior Service Medals, four Legion of Merit Medals, two Meritorious Service Medals, and two Navy and Marine Corps Commendation medals. | | | | | | |
|---|
| | Other Public Company Boards (0) | | | | Board Aptitude | | | | | | |
|---|
| | | | | | The Board believes that Dr. Bono’s decorated military service and distinguished and successful career in trauma surgery and healthcare administration and fiscal management bring an important perspective to Humana’s Board and further contribute to its strategic composition. Dr. Bono’s extensive operational expertise in overseeing large-scale health systems and discipline in managing and advancing healthcare delivery systems and multi-billion dollar enterprises will be vital as the Company continues to evolve its clinical and care delivery strategies. | | | | | | |
|---|
| · · · |
|---|
| | |
|---|
| | 8 | | | Humana | 2026 Proxy Statement • Proposal One | |
|---|
| | | | | | | | | | | | | | | |
|---|
| | Frank A. D’Amelio | | | | Director | | | | Age 68 | Male | White | | | | | |
|---|
| | | | | | Independence | | | | Committees | | | | | |
|---|
| | Independent Director Since 2003 | | | | • Audit Committee (Chair) • Nominating, Governance & Sustainability Committee | | | | |
|---|
| | Skills and Expertise | | | | | | |
|---|
| | • Public Company CFO Experience • Financial Oversight, Capital Allocation and Corporate Transactions • Healthcare Industry Experience | | | | • Government Relations/Public Policy • Risk Assessment • Corporate Governance • Sustainability/ESG | | | | |
|---|
| | Former Executive Vice President, CFO Pfizer Inc. | | | | Professional Summary | | | | | | |
|---|
| | Frank A. D’Amelio was initially elected to the Board in September 2003. Mr. D’Amelio was formerly Executive Vice President, Chief Financial Officer at Pfizer Inc. having held this position from January 2022 until May 2022. Mr. D’Amelio began his career at Pfizer in 2007 and since then has held various roles of increasing responsibility, including, SVP & Chief Financial Officer (September 2007-December 2010), Executive Vice President, Business Operations and Chief Financial Officer (January 2011-October 2018) and Chief Financial Officer and Executive Vice President, Global Supply (November 2018-December 2021). | | | | | | |
|---|
| | | | | | Prior to Pfizer, Mr. D’Amelio was Senior Executive Vice President of Integration and Chief Administrative Officer at Alcatel-Lucent from December 2006 to August 2007, and Chief Operating Officer of Lucent Technologies Inc. from February 2006 to November 2006. From May 2001 until January 2006, he was Executive Vice President, Administration and Chief Financial Officer of Lucent. | | | | | | |
|---|
| | Other Public Company Boards (3) | | | | Board Aptitude | | | | | | |
|---|
| | • Zoetis, Inc. • Hewlett Packard Enterprises • Viatris Inc. | | | | The Board believes that Mr. D’Amelio’s skills, global experience and proven leadership in both financial and operational roles contribute greatly to the Board’s composition. Mr. D’Amelio has served as a senior executive at various global companies undergoing the kind of rapid and complex changes that the Company has undertaken in response to the rapidly changing markets and regulatory environment. His extensive knowledge of the capital markets, strategic investments and transactions and financial risk oversight experience, as well as broad experience working with the investment community, regulatory bodies and rating agencies provide unique and valuable perspective to the Board. | | | | | | |
|---|
| · · · |
|---|
| | |
|---|
| | Proposal One • 2026 Proxy Statement | Humana | | | 9 | |
|---|
| | | | | | | | | | | | | | | |
|---|
| | David T. Feinberg, M.D. | | | | Director | | | | Age 63 | Male | White | | | | | |
|---|
| | | | | | Independence | | | | Committees | | | | | |
|---|
| | Independent Director Since 2022 | | | | • Clinical Quality Committee (Chair) • Nominating, Governance & Sustainability Committee | | | | |
|---|
| | Skills and Expertise | | | | | | |
|---|
| | • Public Company CEO Experience • Financial Oversight, Capital Allocation and Corporate Transactions • Healthcare Industry Experience • IT/Digital; Data Privacy; Cyber Experience | | | | • Marketing/Consumer Insights • Risk Assessment • Corporate Governance • Sustainability/ESG | | | | |
|---|
| | Chairman Oracle Health Former Director, President andCEOCerner Corporation | | | | Professional Summary | | | | | | |
|---|
| | David T. Feinberg, M.D. was initially elected to the Board in March 2022. Dr. Feinberg is Chairman of Oracle Health, where he is committed to making healthcare more accessible, affordable, and equitable. His work advances thought leadership and strategy related to unleashing the healing power of data through an open and connected healthcare ecosystem. Previously, Dr. Feinberg served as President and Chief Executive Officer and member of the Board of Directors of Cerner Corporation (Cerner), which is now Oracle Health. In that role Dr. Feinberg focused on delivering tools and technology to help caregivers optimize the health of their patients and communities. | | | | | | |
|---|
| | | | | | Dr. Feinberg joined Cerner from Google, where he held the position of Vice President of Google Health since 2019 and led Google’s worldwide health efforts, bringing together groups from across Google and Alphabet that used artificial intelligence, product expertise and hardware to tackle some of healthcare’s biggest challenges, and was responsible for organizing and innovating Google’s various healthcare initiatives. Prior to Google, he served as President and CEO of Geisinger Health where he led an operational turnaround, and pushed the use of new platforms and tools, including an IT system called a Unified Data Architecture that allowed the company to integrate big data into existing data analytics and management systems. During his Geisinger tenure, Dr. Feinberg also introduced programs and services to put a greater focus on precision medicine and better patient care. Prior to Geisinger, Dr. Feinberg worked at UCLA for more than 20 years and served in a number of leadership roles, including President, CEO and Associate Vice Chancellor of UCLA Health Sciences, Vice Chancellor and CEO for the UCLA Hospital System, and CEO of UCLA’s Ronald Reagan Medical Center. | | | | | | |
|---|
| | | | | | Dr. Feinberg earned his undergraduate degree at the University of California, Berkeley. He graduated with distinction from the University of Health Sciences/Chicago Medical School. He completed an internship in pediatrics at Loyola University Medical Center, and residency and fellowship training in psychiatry, addiction psychiatry, and child and adolescent psychiatry at the UCLA School of Medicine. He earned a Master of Business Administration from Pepperdine University. Dr. Feinberg is a member of the Alpha Omega Alpha Medical Honor Society, a Distinguished Fellow of American Psychiatric Association and received the Cancro Academic Leadership Award from the American Academy of Child & Adolescent Psychiatry. | | | | | | |
|---|
| | Other Public Company Boards (1) | | | | Board Aptitude | | | | |
|---|
| | • Edwards Lifesciences Corporation | | | | The Board believes that Dr. Feinberg’s experience leading large-scale healthcare organizations focused on leveraging technology and digital innovation to improve clinical care, including public and private companies, brings valuable insights to the Board and further contribute to its strategic composition. His experience leading major corporate transactions as a public company CEO, most notably overseeing the acquisition of Cerner by Oracle, provide the Board with significant transactional and capital allocation expertise. Dr. Feinberg’s clinical background, patient-centric mindset, operating experience, and expertise in guiding systems transformations qualify him to offer key perspectives as the Company continues to advance the integration of its clinical systems and care models to improve the customer experience and reduce costs. | | | | | | |
|---|
| · · · |
|---|
| | |
|---|
| | 10 | | | Humana | 2026 Proxy Statement • Proposal One | |
|---|
| | | | | | | | | | | | | | | |
|---|
| | Wayne A. I. Frederick, M.D. | | | | Director | | | | Age 54 | Male | African American/Black | | | | | |
|---|
| | | | | | Independence | | | | Committees | | | | | |
|---|
| | Independent Director Since 2020 | | | | • Organization & Compensation Committee • Technology Committee | | | | |
|---|
| | Skills and Expertise | | | | |
|---|
| | • Healthcare Industry Experience • Government Relations/Public Policy | | | | • Sustainability/ESG | | | | |
|---|
| | Interim President and President Emeritus Howard University | | | | Professional Summary | | | | |
|---|
| | | | | | Wayne A. I. Frederick, M.D. was initially elected to the Board in February 2020. He is the Interim President of Howard University, having been appointed to serve since September 1, 2025, and President Emeritus having previously served as the 17th President from July 2014-September 2023, and is the distinguished Charles R. Drew Professor of Surgery at the Howard University College of Medicine. He is also a practicing cancer surgeon at Howard University Hospital. Prior to that Dr. Frederick served as Howard University’s Interim President (elected October 2013) after serving as Provost and Chief Academic Officer for more than a year. | | | | | | |
|---|
| | Following his post-doctoral research and surgical oncology fellowships at the University of Texas MD Anderson Cancer Center, Dr. Frederick began his academic career as Associate Director of the Cancer Center at the University of Connecticut. Upon his return to Howard University, his academic positions included Associate Dean in the College of Medicine, Division Chief in the Department of Surgery, Director of the Cancer Center and Deputy Provost for Health Sciences. He also earned a Master of Business Administration degree from Howard University’s School of Business in 2011. | | | | | | |
|---|
| | Dr. Frederick is a fellow of the American College of Surgeons (ACS) and belongs to numerous surgical and medical organizations, including, the ACS’ Academy of Master Surgeon Educators, the American Surgical Association and the National Academy of Medicine. In addition to his public board service, Dr. Frederick also serves on the Board of Directors of Mutual of America Life Insurance Co. | | | | | | |
|---|
| | Other Public Company Boards (4) | | | | Board Aptitude | | | | | | |
|---|
| | • Insulet Corporation • Tempus AI, Inc. • Workday, Inc. • Agostini Limited | | | | The Board believes that Dr. Frederick’s exemplary career as a leader in medical research, healthcare academics and business administration brings valuable insights to the Board to assist in the advancement of its strategic healthcare goals. Dr. Frederick’s extensive healthcare and disease management background will be instrumental to our company’s relationships with our members and our physician partners, as the Company continues to innovate in the area of health data analytics. | | | | | | |
|---|
| · · · |
|---|
| | |
|---|
| | Proposal One • 2026 Proxy Statement | Humana | | | 11 | |
|---|
| | | | | | | | | | | | | | | |
|---|
| | Karen W. Katz | | | | Director | | | | Age 69 | Female | White | | | | |
|---|
| | | | | | Independence | | | | Committees | | | | | |
|---|
| | Independent Director Since 2019 | | | | • Nominating, Governance & Sustainability Committee (Chair) • Organization & Compensation Committee | | | | |
|---|
| | Skills and Expertise | | | | | | |
|---|
| | • Public Company CEO Experience • Financial Oversight, Capital Allocation and Corporate Transactions | | | | • Marketing/Consumer Insights • Risk Assessment • Corporate Governance | | | | |
|---|
| | Former President and CEO Neiman Marcus Group LTD | | | | Professional Summary | | | | |
|---|
| | Karen W. Katz, M.B.A. was initially elected to the Board in September 2019. She was most recently interim CEO of Intermix, LLC from June 2022 to December 2022. Prior to Intermix, Ms. Katz served as the President and CEO of Neiman Marcus Group LTD LLC from 2010 to February 2018. Under Ms. Katz’s leadership, the company executed strategies focused on prioritizing the customer experience and technology integration. Neiman Marcus Group is an international multibrand omni-channel retailer whose portfolio of brands includes Neiman Marcus, Bergdorf Goodman and MyTheresa. Having joined Neiman Marcus in 1985, Ms. Katz served in key executive and leadership roles in the company’s merchant, stores and eCommerce organizations as Executive Vice President — Stores, a member of the Office of the Chairman of Neiman Marcus Group, and President, Neiman Marcus Online, and President and CEO, Neiman Marcus Stores. | | | | | | |
|---|
| | | | | | | | |
|---|
| | Other Public Company Boards (1) | | | | Board Aptitude | | | | | | |
|---|
| | • The RealReal, Inc. (Chairperson) | | | | The Board believes that Ms. Katz is an extremely accomplished executive with deep experience in financial oversight and corporate transactions, derived from leading a multi-billion dollar enterprise through complex financial transactions. Beyond her demonstrated commitment to understanding, and meeting, the needs of customers by maintaining a personalized experience enabled by digital transformation, she brings a holistic approach to customer service, including acumen for employing technology to advance service delivery, combined with demonstrated success in growing business through forward thinking leadership, providing valuable perspective and expertise to the Board. | | | | |
|---|
| · · · |
|---|
| | |
|---|
| | 12 | | | Humana | 2026 Proxy Statement • Proposal One | |
|---|
| | | | | | | | | | | | | | | |
|---|
| | Marcy S. Klevorn | | | | Director | | | | Age 66 | Female | White | | | | | |
|---|
| | | | | | Independence | | | | Committees | | | | | |
|---|
| | Independent Director Since 2021 | | | | • Technology Committee (Chair) • Audit Committee | | | | |
|---|
| | Skills and Expertise | | | | | | |
|---|
| | • Financial Oversight, Capital Allocation and Corporate Transactions • IT/Digital; Data Privacy; Cyber Experience • Marketing/Consumer Insights | | | | • Risk Assessment • Corporate Governance • Sustainability/ESG | | | | | | |
|---|
| | Former Chief Transformation Officer Ford Motor Company | | | | Professional Summary | | | | | | |
|---|
| | Marcy S. Klevorn was initially elected to the Board in February 2021. Ms. Klevorn was formerly the Chief Transformation Officer of Ford Motor Company from May 2019 until her retirement in October 2019. In this role, she accelerated the company’s transformation by helping to refine its corporate governance systems, facilitate faster adoption of agile teams across the business and ensure process improvements across the enterprise. She also facilitated strategic partnerships with key technology partners and supported the company’s diversity efforts. Having joined Ford Motor Company in 1983, Ms. Klevorn served in key executive and leadership roles within the company’s information technology organization including Director of the Office of the Chief Information Officer and Group Vice President of Information Technology. Ms. Klevorn also served as Executive Vice President and President of Ford Smart Mobility LLC, a division of Ford Motor Company, where she oversaw certain acquisitions and other investments and helped to accelerate the company’s plans to design, build, grow and invest in emerging mobility services and global data insight and analytics. | | | | | | |
|---|
| | | | | | | | |
|---|
| | Other Public Company Boards (2) | | | | Board Aptitude | | | | | | |
|---|
| | • Northern Trust Corporation • Cerence Inc. | | | | The Board believes that Ms. Klevorn’s extensive executive experience and leadership in digital innovation, systems transformation, financial oversight and capital deployment brings valuable insights to the Board as the Company continues to enhance its technology-driven platforms for members and providers. Ms. Klevorn’s deep understanding of information technology, cyber security, and systems management and infrastructure, combined with her proven ability to connect systems to strategy execution qualify her to provide key insights in the Company’s consumer-focused approach to care. | | | | |
|---|
| · · · |
|---|
| | |
|---|
| | Proposal One • 2026 Proxy Statement | Humana | | | 13 | |
|---|
| | | | | | | | | | | | | | | |
|---|
| | Jorge S. Mesquita | | | | Director | | | | Age 64 | Male | White | | | | |
|---|
| | | | | | Independence | | | | Committees | | | | | |
|---|
| | Independent Director Since 2021 | | | | • Investment Committee • Clinical Quality Committee | | | | |
|---|
| | Skills and Expertise | | | | | | |
|---|
| | • Healthcare Industry Experience • Marketing/Consumer Insights • Sustainability/ESG | | | | | | | | |
|---|
| | Former Chief Executive Officer Blue Triton Brands Former Executive Vice President, Worldwide Chairman, Consumer Johnson & Johnson | | | | Professional Summary | | | | |
|---|
| | Jorge S. Mesquita was initially elected to the Board in February 2021. Mr. Mesquita was formerly Chief Executive Officer of BlueTriton Brands, from July 2021 until March 2022. In this role Mr. Mesquita led the company’s initiatives to expand market leadership, advance commitment to sustainability and environmental stewardship and to realize the potential of the company’s portfolio of water brands. | | | | | | |
|---|
| | | | | | Prior to joining BlueTriton Brands, Mr. Mesquita was formerly the Executive Vice President, Worldwide Chairman, Consumer of Johnson & Johnson (J&J), from December 2014 until February 2019, where he was responsible for increasing competition within J&J’s consumer business through a comprehensive transformational strategy. In this role, Mr. Mesquita served on J&J’s Executive Committee and led the Consumer Group Operating Committee. Prior to that, Mr. Mesquita was employed by The Procter & Gamble Company (P&G), where he held various marketing and leadership positions for 29 years from 1984 to 2013. During his tenure at P&G, Mr. Mesquita served as Group President — New Business Creation and Innovation from March 2012 until June 2013, Group President — Special Assignment from January 2012 until March 2012, Group President, Global Fabric Care from 2007 to 2011 and President, Global Home Care from 2001 to 2007, also serving as President of Commercial Products and President of P&G Professional from 2006 to 2007. | | | | | | |
|---|
| | Other Public Company Boards (1) | | | | Board Aptitude | | | | | | |
|---|
| | • Mondelez International, Inc. | | | | The Board believes that Mr. Mesquita’s proven experience in leading business units for significant global, consumer-oriented companies provides a valuable perspective to Humana’s Board and further contribute to its strategic composition. Mr. Mesquita’s forward-thinking, transformational mindset and strong track record of building and marketing global brands, developing consumer insight-driven innovation capabilities, and driving strong, profitable growth will be essential as the Company continues to create seamless consumer experiences and help its members achieve their best health. | | | | | | |
|---|
| · · · |
|---|
| | |
|---|
| | 14 | | | Humana | 2026 Proxy Statement • Proposal One | |
|---|
